Medicenna BioPharma

Medicenna Therapeutics is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of natural interleukins, which they call "Superkines." Their lead program, MDNA55, is an IL-4-targeted toxin that has completed Phase 2b trials for recurrent glioblastoma and is preparing for Phase 3. The company's platform also includes MDNA11, a next-generation IL-2 Superkine designed to selectively activate cancer-fighting immune cells without the toxic side effects of native IL-2. Medicenna aims to address unmet needs in oncology and autoimmune diseases by engineering cytokines with improved safety and efficacy profiles.